Drug intelligence / Profile preview

ibrutinib + anti-CD19 CAR-T cells

Development stage: Unknown
Lead developer: The Affiliated Hospital of Xuzhou Medical University
Modality: Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Oral, Intravenous

Overview

BTK inhibitor + Anti-CD19 CAR T cells is an investigational combination therapy regimen that pairs the small-molecule Bruton's tyrosine kinase (BTK) inhibitor ibrutinib with chimeric antigen receptor (CAR) T cells targeting the CD19 antigen. Ibrutinib, a covalent inhibitor of BTK, disrupts B-cell receptor signaling and has been shown to enhance CAR-T cell function by promoting proliferation, enriching for less-differentiated T-cell phenotypes, and downregulating exhaustion markers. Additionally, ibrutinib may reduce the severity of cytokine release syndrome (CRS), a common side effect of CAR-T therapy. This combination is primarily being evaluated for the treatment of relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma (B-NHL), where it aims to improve the overall response rate and durability of treatment compared to CAR-T therapy alone.

Other names: BTK inhibitor + Anti-CD19 CAR T cellsibrutinib + anti-CD19 CAR-TBTKi + Anti-CD19 CAR-Tibrutinib + anti-CD19 CAR-T cells

Targets

CD19 (B lymphocyte antigen CD19)BTK (Bruton tyrosine kinase)ITK (Interleukin 2-inducible T-cell kinase)ErbB (EGFR family)SFK (SRC family kinases)

Beyond the preview

Go deeper on ibrutinib + anti-CD19 CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibrutinib + anti-CD19 CAR-T cells.

Explore the full profile